Salix wins OK for ulcerative colitis therapy; Isis bags $18M milestone from GSK;

@FierceBiotech: VC giant NEA recruits a biotech vet to join its ranks of dealmakers. Report | Follow @FierceBiotech

@JohnCFierce: Biotechs tap a swelling tide of investment cash to fund growing R&D ops--or, laissez les bon temps rouler. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. Release | Follow @DamianFierce

@EmilyMFierce: Ebola genome browser launched to aid drug discovery. FierceBiotech Research story | Follow @EmilyMFierce

> Widely viewed as a likely takeover target, Salix Pharmaceuticals ($SLXP) has nabbed an FDA approval for Uceris, a rectal foam therapy for ulcerative colitis. The therapy is an extended-release version of budesonide. The treatment is a rectally applied corticosteroid. Release

> Carlsbad, CA-based Isis Pharmaceuticals ($ISIS) bagged an $18 million milestone payment from GlaxoSmithKline ($GSK) on the progress for the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. Release

Medical Device News

@FierceMedDev: Histogenics files for IPO, as Autogenomics refiles again. Article | Follow @FierceMedDev

@VarunSaxena2: HillaryClinton says we have to review +s and -s of device tax. An expected non-answer. | Follow @VarunSaxena2

@EmilyWFierce: Third time's a charm? FDA panel recommends Boston Scientific's Watchman device by a slim margin. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in #cancer cells. More | Follow @MichaelGFierce

> Boston Scientific wins positive recommendation from FDA panel for stroke-fighting Watchman device. More

> Stealth surgical reconstruction startup Tela-Bio raises $45.4 million. Item

> CoheroHealth to pilot asthma inhaler sensor and app at Mount Sinai Medical Center. Article

Pharma News

@FiercePharma: Top-read in FP Weds: Novartis, GSK shake up executive ranks as overhaul continues. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI, this week's issue of FiercePharmaMarketing is here. And you can subscribe here. | Follow @CarlyHFierce

> Merck can't sidestep $250M gender-bias suit, judge says. Story

> Auxilium dumps QLT inversion deal for $2.6B Endo buyout. Article

Vaccines News

> Pfizer's meningitis B vaccine is effective when given with HPV jab. More

> Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant. Story

> Biotechs angling for T-cell response in race for next-gen herpes vaccine. Article

> Takeda appoints new vax development head as Novartis' Oswald heads for the door. Report

> Could 'space bacteria' help create vaccines? Item

Pharma Manufacturing News

> Impax says $700M deal for Tower will help it deal with quality issues. More

> Hospira recalls drug because of storage glitch during shipping. Report

> France's Ceva has completed a sterile facility for vet drugs. Item

> Gerresheimer adjusts earnings forecast lower in wake of FDA crackdown. Article

> CSL announces $450M commitment to expand two of its plants. Story

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.